Pacira BioSciences Newsroom

We Think That There Are Issues Underlying Pacira BioSciences' (NASDAQ:PCRX) Earnings

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) stock was strong after they recently reported robust earnings. However, we think that shareholders may be missing some concerning details in the numbers. N

Simply Wall StMay 14 06:26 ET

Express News | Pacira BioSciences Reveals Pricing Of $250.0M Aggregate Principal Amount Of 2.125% Convertible Senior Notes Due 2029

BenzingaMay 10 07:12 ET

Express News | Pacira Convertible Senior Notes Maturity Set for May 15, 2029

ReutersMay 10 07:06 ET

Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes Due 2029

PDF Version TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior no

Pacira BioSciencesMay 10 00:00 ET

Pacira Biosciences Announces Proposed Offering of $250M Aggregate Principal Amount of Convertible Senior Notes

Seeking AlphaMay 8 16:36 ET

Express News | Pacira Biosciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

ReutersMay 8 16:05 ET

Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate princ

GlobeNewswireMay 8 16:05 ET

Pacira BioSciences Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Pacira BioSciences Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow JonesMay 8 15:35 ET

Express News | HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target

BenzingaMay 8 15:25 ET

Pacira BioSciences Is Maintained at Overweight by Barclays

Pacira BioSciences Is Maintained at Overweight by Barclays

Dow JonesMay 8 14:22 ET

Pacira BioSciences Price Target Cut to $38.00/Share From $40.00 by Barclays

Pacira BioSciences Price Target Cut to $38.00/Share From $40.00 by Barclays

Dow JonesMay 8 14:22 ET

Express News | Barclays Maintains Overweight on Pacira BioSciences, Lowers Price Target to $38

BenzingaMay 8 14:11 ET

Analyst Ratings For Pacira BioSciences

6 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:PCRX) during the recent three months, expressing a mix of bullish and bearish perspectives.Summarizing their recent assessments,

BenzingaMay 8 14:00 ET

Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating

Pacira BioSciences (PCRX) has an average rating of outperform and price targets ranging from $36 to $57, according to analysts polled by Capital IQ. Price: 30.05, Change: +3.54, Percent Change: +13.35

MT NewswiresMay 8 10:34 ET

Pacira Biosciences Up Nearly 12%, On Track for Largest Percent Increase Since November 2020 -- Data Talk

Pacira Biosciences, Inc. (PCRX) is currently at $29.64, up $3.14 or 11.83% --Would be highest close since March 20, 2024, when it closed at $30.02 --On pace for largest percent increase since Nov. 9

Dow JonesMay 8 10:32 ET

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 8 09:33 ET

Express News | Pacira Biosciences Inc : Barclays Cuts Target Price to $38 From $40

ReutersMay 8 07:44 ET

Pacira BioSciences Is Maintained at Buy by Needham

Pacira BioSciences Is Maintained at Buy by Needham

Dow JonesMay 8 06:48 ET

Pacira BioSciences Price Target Cut to $43.00/Share From $45.00 by Needham

Pacira BioSciences Price Target Cut to $43.00/Share From $45.00 by Needham

Dow JonesMay 8 06:48 ET

Express News | Pacira Biosciences Inc : Needham Cuts Target Price to $43 From $45

ReutersMay 8 06:45 ET